Kartos Therapeutics IPO

www.kartosthera.com

Kartos Therapeutics is a clinical stage biopharmaceutical company with a potential best-in-class MDM2 inhibitor (KRT-232) in clinical development, across a variety of TP53 wild-type hematological malignancies and solid tumors.

Founded2017
Register for Details

For more details on financing and valuation for Kartos Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Kartos Therapeutics Ticker Symbol

Kartos Therapeutics does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Kartos Therapeutics Stock Price

The stock price for Kartos Therapeutics will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Other companies like Kartos Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM